Driving smarter direct-to-patient engagement through a customer lifetime value lens
Key takeaways:
- Direct-to-patient (DTP) growth requires a shift from patient volume to patient value. As acquisition costs rise and patient expectations increase, one-size-fits-all engagement becomes less effective and more expensive.
- Customer lifetime value (CLV) brings economic discipline to DTP decisions. Forward-looking CLV models help pharma identify differences in patients’ expected value, persistence and engagement needs and invest accordingly.
- The real value comes from activation, not the score itself. CLV must shape patient journeys, service levels, retention efforts and resource allocation across marketing, finance, sales and patient services.
- Pharma can start small and scale what works. A practical path begins with auditing the existing patient base, building a model where data is strongest, testing value-based engagement in one journey and institutionalizing proven approaches.
As DTP models expand, pharma companies need a more disciplined way to decide which patients to engage, how to serve them and where to invest. This white paper explores how CLV can help organizations move beyond broad, one-size-fits-all programs toward patient engagement informed by predicted future value, persistence and needs.
Learn how to apply CLV across acquisition, retention, patient services and investment decisions; translate patient-level data into actionable segments; and embed CLV as a shared metric across commercial functions.
Drawing on ZS’s pharmaceutical expertise and Theta’s customer-value science, the paper also outlines the data, analytics, technology and operating-model capabilities required to put CLV into practice and build more personalized, effective and sustainable patient relationships.
